We Offer Worldwide Shipping
Login Wishlist

Dehydrochromolaenin

$896

  • Brand : BIOFRON

  • Catalogue Number : BN-B0392

  • Specification : 95%(HPLC)

  • CAS number : 20013-76-7

  • Formula : C15H14O

  • Molecular Weight : 210.27

  • PUBCHEM ID : 12309959

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-B0392

Analysis Method

HPLC,NMR,MS

Specification

95%(HPLC)

Storage

-20℃

Molecular Weight

210.27

Appearance

Powder

Botanical Source

This product is isolated and purified from the rhizomes of Curcuma zedoaria

Structure Type

Sesquiterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC1=CC2=C(C=C1)C(=CC3=C2C(=CO3)C)C

Synonyms

Naphtho[2,1-b]furan, 1,5,8-trimethyl-/1,5,8-Trimethylnaphtho[2,1-b]furan

IUPAC Name

1,5,8-trimethylbenzo[e][1]benzofuran

Density

1.1±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

173.9±6.1 °C

Boiling Point

350.7±11.0 °C at 760 mmHg

Melting Point

98-100℃

InChl

InChI=1S/C15H14O/c1-9-4-5-12-10(2)7-14-15(13(12)6-9)11(3)8-16-14/h4-8H,1-3H3

InChl Key

UYXJESJBZRIFPL-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:20013-76-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

11461067

Abstract

Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months and 38/69 patients have died. Grade III-IV toxicity was acceptable. Leukopenia occurred in 26% of patients, thrombocytopenia in 2% and anaemia in 4%. One patient had reversible heart failure during FEC therapy. Peripheral neuropathy and arthralgia-myalgia occurred in 9% and 4% of patients, respectively and one patient had respiratory hypersensitivity during paclitaxel treatment. 9 patients did not complete therapy because of: treatment refusal (n= 1), cardiac toxicity (n= 1), early death during FEC chemotherapy (n= 1), major protocol violations (n= 4), hypersensitivity reaction (n= 1) and early death during paclitaxel chemotherapy (n= 1). The overall response rate was 65% (95% CI = 53-76), and 7% of patients had stable disease. Therapy was defined as having failed in 28% of patients because they were not evaluable (13%) or had progressive disease (15%). The median time to progression and survival are 13.2 and 23.5 months, respectively. Sequential FEC-paclitaxel is a suitable strategy for patients with metastatic breast cancer who have not been previously treated with anthracyclines and/or taxanes. In fact, it avoids major haematologic toxicity and has a good antitumour effect. © 2001 Cancer Research Campaign http://www.bjcancer.com

KEYWORDS

advanced breast cancer, anthracycline-containing regimen, paclitaxel, sequential chemotherapy

Title

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

Author

A Riccardi,1 P Pugliese,1 M Danova,1 S Brugnatelli,1 D Grasso,1 M Giordano,2 G Bernardo,3 G Giardina,4 S Fava,5 G Montanari,6 C Pedrotti,7 G Trotti,8 E Rinaldi,9 M A Poli,10 and C Tinelli11

Publish date

2001 Jul;

PMID

10755397

Abstract

We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57-2.42;P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months;P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. © 2000 Cancer Research Campaign

KEYWORDS

multiple myeloma, stage I, early or delayed treatment, survival

Title

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study

Author

A Riccardi,1 O Mora,1 C Tinelli,2 D Valentini,1 S Brugnatelli,1 R Spanedda,3 A De Paoli,4 L Barbarano,5 M Di Stasi,6 M Giordano,7 C Delfini,8 G Nicoletti,9 C Bergonzi,10 E Rinaldi,11 L Piccinini,12 E Ascari,1 and for the Co-operative Group of study and Treatment of Multiple Myeloma

Publish date

2000 Apr;

PMID

30627045

Abstract

A taxonomic treatment, phylogeny based on analysis of six DNA sequence markers (ITS, ndhA intron, rpl32-trnL, rps3, rps16 intron and rps16-trnK) and classification of Muhlenbergia for Peru is given. Seventeen species and one presumed hybrid are recognised. Muhlenbergiaromaschenkoisp. nov. is newly described from the Rio Huallaga Valley, northeast of Huanuco. The type of Podosemumangustatum [≡ Muhlenbergiaangustata] clearly aligns with what we had been referring to as the hybrid between this species and M.rigida. Therefore, we adopt the next available heterotypic name, Muhlenbergiacoerulea, for what we had been calling M.angustata and change the hybrid designation to M.coerulea × M.rigida. Lectotypes are designated for Epicampescoerulea Griseb., Muhlenbergiaaffinis Trin., Muhlenbergiaberlandieri Trin., Muhlenbergiabeyrichiana Kunth, Muhlenbergiaelegansvar.atroviolacea Kuntze, Muhlenbergiaelegansvar.subviridis Kuntze and Muhlenbergiaphragmitoides Griseb.

KEYWORDS

classification, ITS, lectotypification, Muhlenbergia , Peru, phylogeny, plastid DNA sequences, Poaceae , systematics, taxonomy

Title

Revision of Muhlenbergia (Poaceae, Chloridoideae, Cynodonteae, Muhlenbergiinae) in Peru: classification, phylogeny, and a new species, M.romaschenkoi

Author

Paul M. Peterson,corresponding author1 Isidoro Sanchez Vega,2 Konstantin Romaschenko,1 Diego Giraldo-CaNas,3 and Nancy F. Refulio Rodriguez4

Publish date

2018;


Description :

Empty ...